Insulin aspart, a human insulin analogue, is a rapid-acting, parenteral blood glucose-lowering agent. Insulin aspart was marketed under the brand name NovoLog for the treatment of adult patients with diabetes mellitus, for the control of hyperglycemia. The primary activity of the drug is the regulation of glucose metabolism. Insulin aspart binds to the insulin receptors on muscle and fat cells and lower blood glucose by facilitating the cellular uptake of glucose and simultaneously inhibiting the output of glucose from the liver. This drug has an off-label treatment for gestational diabetes (temporary diabetes caused by diabetes).
Approval Year
PubMed
Sample Use Guides
NovoLog™ (insulin aspart) should be administered by subcutaneous injection in the abdominal wall, the thigh, or the upper arm. Injection sites should be rotated within the same region. As with all insulins, the duration NovoLog™ should generally be given immediately before a meal. The dosage of NovoLog™ should be individualized and determined, based on the physician's advice, in accordance with the needs of the patient. The total daily individual insulin requirement is usually between 0.5 - 1.0
units/kg/day.
Route of Administration:
Other
Subunit 0
Subunit 1
